Ph2/3 study of BMS-986507 in patients with TNBC
Phase II/III Clinical Trial
IZABRIGHT-Breast01: A Randomized Open-label Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician's Choice in Patients with Previously Untreated Locally Advanced Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment (CA244-0008)
Participating Locations